| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.35 | 2e-05 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0001 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.1 | 0.0006 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.24 | 0.001 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.096 | 0.002 |